Tak Don Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tak Don Kim has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jang Hee Hong
Clinical Trials Center, Chungnam National University Hospital, Daejeon 35015, Republic of Korea
2 shared publications - Jung Sunwoo
Clinical Trials Center, Chungnam National University Hospital, Daejeon 35015, Republic of Korea
2 shared publications Chan Song Park
Seoul National University College of Medicine
1 shared publication- Cheol Joong Kim
Clinical Trials Center, Chungnam National University Hospital, Daejeon 35015, Korea
1 shared publication Ho-Sook Kim
Inje University College of Medicine
1 shared publication- Jae-Gook Shin
Center for Personalized Precision Medicine of Tuberculosis, Inje University College of Medicine, Busan 47392, Republic of Korea
1 shared publication
Latest Publications
- 13 August 2025
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 26 (10-12) , 367-376
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations
Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme responsible for metabolizing approximately 20% of commonly prescribed drugs. Its genetic variability contributes to interindividual and interethnic differences in drug response. However, large-scale studies on CYP2D6 allele distributions in the Korean population remain limited. We conducted CYP2D6 genotyping, including copy number variation analysis, in 3,874 unrelated Korean individuals recruited from five university hospitals. Genotypes were assigned diplotypes and phenotypes using the CPIC activity score system. The most frequent allele was the decreased-function *10 (44.9%), followed by normal-function *1 (32.8%) and 2 (11.0%). The gene deletion five accounted for 5.7%. Among phenotypes, 62.2% were extensive metabolizers, 36.1% intermediate metabolizers, 0.9% ultrarapid metabolizers, and 0.4% poor metabolizers. We also identified CYP2D6 × 65, previously unreported in Koreans, and a novel duplication variant, CYP2D6 × 49x2. This is the largest study of CYP2D6 polymorphisms in a Korean population to date. It provides a comprehensive reference for Korean pharmacogenomics and highlights important interethnic differences. The findings support the development of personalized medicine strategies based on population-specific pharmacogenetic data.
- 13 August 2025
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 26 (10-12) , 367-376
CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations
Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic enzyme responsible for metabolizing approximately 20% of commonly prescribed drugs. Its genetic variability contributes to interindividual and interethnic differences in drug response. However, large-scale studies on CYP2D6 allele distributions in the Korean population remain limited. We conducted CYP2D6 genotyping, including copy number variation analysis, in 3,874 unrelated Korean individuals recruited from five university hospitals. Genotypes were assigned diplotypes and phenotypes using the CPIC activity score system. The most frequent allele was the decreased-function *10 (44.9%), followed by normal-function *1 (32.8%) and 2 (11.0%). The gene deletion five accounted for 5.7%. Among phenotypes, 62.2% were extensive metabolizers, 36.1% intermediate metabolizers, 0.9% ultrarapid metabolizers, and 0.4% poor metabolizers. We also identified CYP2D6 × 65, previously unreported in Koreans, and a novel duplication variant, CYP2D6 × 49x2. This is the largest study of CYP2D6 polymorphisms in a Korean population to date. It provides a comprehensive reference for Korean pharmacogenomics and highlights important interethnic differences. The findings support the development of personalized medicine strategies based on population-specific pharmacogenetic data.
- Open Access
- 1 January 2025
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 33 (1) , 19-26
Clinical data warehouse analysis of clinical laboratory test results of Korean healthy volunteers: does “not clinically significant” range of healthy volunteers need modification?
Kim CJ, et al. Transl Clin Pharmacol. 2025 Mar;33(1):19-26. https://doi.org/10.12793/tcp.2025.33.e2
- 1 January 2025
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 33 (1) , 19-26
Open AccessClinical data warehouse analysis of clinical laboratory test results of Korean healthy volunteers: does “not clinically significant” range of healthy volunteers need modification?
Kim CJ, et al. Transl Clin Pharmacol. 2025 Mar;33(1):19-26. https://doi.org/10.12793/tcp.2025.33.e2